Armata Pharmaceuticals to Present at the Oppenheimer 31st Annual Healthcare Conference

Armata Pharmaceuticals (NYSE American: ARMP) announces participation in the Oppenheimer 31st Annual Healthcare Conference from March 16-18, 2021.

Rhea-AI Summary

Armata Pharmaceuticals (NYSE American: ARMP) announces participation in the Oppenheimer 31st Annual Healthcare Conference from March 16-18, 2021. Management will present on March 17 at 3:10pm ET. The company focuses on bacteriophage therapeutics targeting antibiotic-resistant bacterial infections, with a diverse pipeline including candidates for Pseudomonas aeruginosa and Staphylococcus aureus. Armata collaborates with Merck to develop synthetic phage candidates for an undisclosed infectious disease.

Argus Session date unavailable

+0.72% session move Open Argus

Details

News Market Reaction – ARMP

The recorded move for ARMP in the trading session of this news was +0.72%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

MARINA DEL REY, Calif., March 16, 2021 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced that the Company will participate in the Oppenheimer 31^st Annual Healthcare Conference taking place virtually March 16-18, 2021.

Management is scheduled to present at 3:10pm ET on Wednesday, March 17.

About Armata Pharmaceuticals, Inc.

Armata is a clinical-stage biotechnology company focused on the development of precisely targeted bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. Armata is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, known as MSD outside of the United States and Canada, Armata is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent. Armata is committed to advancing phage with drug development expertise that spans bench to clinic including in-house phage specific GMP manufacturing.  

Media Contacts:

At Armata:
Steve Martin
Armata Pharmaceuticals, Inc.
ir@armatapharma.com
858-800-2492

Investor Relations:
Joyce Allaire
LifeSci Advisors, LLC
jallaire@lifesciadvisors.com
212-915-2569

View original content to download multimedia:http://www.prnewswire.com/news-releases/armata-pharmaceuticals-to-present-at-the-oppenheimer-31st-annual-healthcare-conference-301248516.html

SOURCE Armata Pharmaceuticals, Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When is Armata Pharmaceuticals presenting at the Oppenheimer Conference?

Armata Pharmaceuticals will present on March 17, 2021, at 3:10pm ET.

What is the main focus of Armata Pharmaceuticals?

Armata Pharmaceuticals specializes in pathogen-specific bacteriophage therapeutics for antibiotic-resistant bacterial infections.

Who is collaborating with Armata Pharmaceuticals on phage development?

Armata is collaborating with Merck to develop proprietary synthetic phage candidates.

What pathogens are included in Armata's clinical pipeline?

Armata's pipeline includes clinical candidates for Pseudomonas aeruginosa and Staphylococcus aureus.

What dates is the Oppenheimer 31st Annual Healthcare Conference taking place?

The conference is held from March 16 to March 18, 2021.